Imaging nigral pathology and clinical progression in Parkinson's disease
暂无分享,去创建一个
Martin Styner | Xuemei Huang | Guangwei Du | Michele L. Shaffer | Qing X. Yang | M. Styner | Mechelle M Lewis | Xuemei Huang | Jianli Wang | G. Du | S. Sen | M. Shaffer | Suman Sen | Mechelle M. Lewis | Jianli Wang | M. Lewis | Xuemei Huang
[1] Dorothee P Auer,et al. T1‐Weighted MRI shows stage‐dependent substantia nigra signal loss in Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.
[2] A. Graybiel,et al. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. , 1999, Brain : a journal of neurology.
[3] Q. Pankhurst,et al. Looking for biogenic magnetite in brain ferritin using NMR relaxometry , 2005, NMR in biomedicine.
[4] R. Ordidge,et al. Increased iron‐related MRI contrast in the substantia nigra in Parkinson's disease , 1995, Neurology.
[5] Janey Prodoehl,et al. Effects of aging on the ventral and dorsal substantia nigra using diffusion tensor imaging , 2012, Neurobiology of Aging.
[6] Marguerite Wieler,et al. Midbrain iron content in early Parkinson disease , 2008, Neurology.
[7] J. Hughes,et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.
[8] Martin Styner,et al. Combined R2* and Diffusion Tensor Imaging Changes in the Substantia Nigra in Parkinson's Disease , 2011, Movement disorders : official journal of the Movement Disorder Society.
[9] E.M. Haacke,et al. Characterizing the Mesencephalon Using Susceptibility-Weighted Imaging , 2009, American Journal of Neuroradiology.
[10] M. B. Spraker,et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease , 2009, Neurology.
[11] D. Brooks,et al. Core assessment program for intracerebral transplantations (CAPIT) , 1992, Movement disorders : official journal of the Movement Disorder Society.
[12] Alberto Albertini,et al. Neuromelanin can protect against iron‐mediated oxidative damage in system modeling iron overload of brain aging and Parkinson’s disease , 2008, Journal of neurochemistry.
[13] S Fook-Chong,et al. Case control study of diffusion tensor imaging in Parkinson’s disease , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.
[14] A. Lees,et al. Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.
[15] Lisa Kuramoto,et al. Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis. , 2004, Archives of neurology.
[16] C. Marsden,et al. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia , 1992 .
[17] A. Graybiel,et al. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. , 1999, Brain : a journal of neurology.
[18] A. Lang. The progression of Parkinson disease , 2007, Neurology.
[19] D. Calne,et al. Patterns of Asymmetry Do Not Change Over the Course of Idiopathic Parkinsonism , 1995, Neurology.
[20] A. Roch,et al. Relaxation induced by ferritin and ferritin‐like magnetic particles: The role of proton exchange , 2000, Magnetic resonance in medicine.
[21] D. Mikulis,et al. A new sensitive imaging biomarker for Parkinson disease? , 2009, Neurology.
[22] Paul M. Matthews,et al. MRI characteristics of the substantia nigra in Parkinson's disease: A combined quantitative T1 and DTI study , 2009, NeuroImage.
[23] P D Griffiths,et al. Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. , 2000, Brain : a journal of neurology.
[24] Yi Wang,et al. Quality control of diffusion weighted images , 2010, Medical Imaging.
[25] M Schulzer,et al. Clinical observations on the rate of progression of idiopathic parkinsonism. , 1994, Brain : a journal of neurology.
[26] S. Ropele,et al. Quantitative MR imaging of brain iron: a postmortem validation study. , 2010, Radiology.
[27] C. Clarke,et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[28] E. Hirsch,et al. Neuromelanin associated redox‐active iron is increased in the substantia nigra of patients with Parkinson's disease , 2003, Journal of neurochemistry.
[29] Khader M. Hasan,et al. Quantitative diffusion tensor imaging detects dopaminergic neuronal degeneration in a murine model of Parkinson’s disease , 2007, Neurobiology of Disease.
[30] P. Riederer,et al. Iron-binding characteristics of neuromelanin of the human substantia nigra. , 2003, Biochemical pharmacology.
[31] William W. Boonn,et al. Medical Imaging 2010: Advanced PACS-based Imaging Informatics and Therapeutic Applications , 2010 .
[32] Qing X Yang,et al. MRI and histological analysis of beta‐amyloid plaques in both human Alzheimer's disease and APP/PS1 transgenic mice , 2009, Journal of magnetic resonance imaging : JMRI.
[33] C. Marsden,et al. Complex I, Iron, and ferritin in Parkinson's disease substantia nigra , 1994, Annals of neurology.
[34] Yoshiharu Tamakawa,et al. The substantia nigra in Parkinson disease: proton density-weighted spin-echo and fast short inversion time inversion-recovery MR findings. , 2002, AJNR. American journal of neuroradiology.
[35] Andreas Schäfer,et al. High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson's disease , 2012, Journal of magnetic resonance imaging : JMRI.
[36] Peter Riederer,et al. Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.
[37] E. Bullmore,et al. Formal characterization and extension of the linearized diffusion tensor model , 2005, Human brain mapping.
[38] Daniel Rueckert,et al. Nonrigid registration using free-form deformations: application to breast MR images , 1999, IEEE Transactions on Medical Imaging.
[39] B. Halliwell. Oxygen radicals as key mediators in neurological disease: Fact or fiction? , 1992, Annals of neurology.
[40] G. Reynolds,et al. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain , 2005, Journal of Neural Transmission.
[41] Z. Cho,et al. Seven‐tesla magnetic resonance images of the substantia nigra in Parkinson disease , 2012, Annals of neurology.
[42] A. Stefani,et al. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. , 2010, Brain : a journal of neurology.
[43] J. Connor,et al. Iron, brain ageing and neurodegenerative disorders , 2004, Nature Reviews Neuroscience.
[44] Guido Gerig,et al. User-guided 3D active contour segmentation of anatomical structures: Significantly improved efficiency and reliability , 2006, NeuroImage.
[45] T A Yousry,et al. Anatomy of the substantia nigra and subthalamic nucleus on MR imaging. , 2010, Neuroimaging clinics of North America.
[46] Andrew J. Lees,et al. Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease , 2001, Neurology.
[47] E. Haacke,et al. Imaging iron stores in the brain using magnetic resonance imaging. , 2005, Magnetic resonance imaging.